Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Wayne Kuznar
Authored Items
ASCO 2021 Presidential Address: Eliminating Disparities in Cancer Care
Wayne Kuznar
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Disparities in Cancer Care
,
Conference Highlights ASCO
New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
,
Conference Highlights ASCO
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
Wayne Kuznar
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Melanoma
,
Conference Highlights ASCO
Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer
Wayne Kuznar
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Conference Highlights ASCO
Zanidatamab Shows Promising Activity in Patients with HER2-Overexpressing Gastric Cancers
Wayne Kuznar
Web Exclusives
Umbralisib plus Ublituximab Combination Superior to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Oral Azacitidine Extends Survival in Acute Myeloid Leukemia, Regardless of MRD Status, in Patients in Remission After Chemotherapy
Wayne Kuznar
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Magrolimab, First CD47 Antibody, Shows Promise in Combination with Azacitidine in Unfit Patients with Acute Myeloid Leukemia
Wayne Kuznar
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Pevonedistat plus Azacitidine Combination Improves Outcomes versus Azacitidine Monotherapy in High- Risk Myelodysplastic Syndromes
Wayne Kuznar
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment
Wayne Kuznar
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Value-Based Care
Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma
Wayne Kuznar
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
Olaparib Extends Survival by >1 Year in Patients with Ovarian Cancer and BRCA Mutation, Ushering in Personalized Medicine in This Malignancy
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Ovarian Cancer
ASCO 2020 Presidential Address: Accelerating Progress, Prioritizing Diversity
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Value-Based Care
Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Lung Cancer
Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Lung Cancer
Tumor-Infiltrating Lymphocyte Therapy Induces Responses Across Wide Range of Patients with Advanced Melanoma
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular and Marginal-Zone Lymphoma
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
,
Lymphoma
Preparing for Healthcare After COVID-19: New Challenges Facing Payers
Wayne Kuznar
June 2020 Vol 13, No 3
in
Industry Trends
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Conference Highlights ASH
Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
in
Lymphoma
Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Lung Cancer
Larotrectinib Has Wide-Ranging Efficacy in Advanced Solid Tumors with NTRK Gene Fusion
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Biomarkers
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Cholangiocarcinoma
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Emerging Therapies
Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Emerging Therapies
ASCO 2019 Presidential Address: Removing Disparities in Cancer Care
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Disparities in Oncology
The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Pediatric Cancer
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
in
Lung Cancer
Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Leukemia
AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Emerging Therapies
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Lymphoma
Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
in
Emerging Therapies
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
August 2018 Vol 11, Special Issue
Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer See also Value-Based Care
Wayne Kuznar
August 2018 Vol 11, Special Issue
in
Lung Cancer
Precision Medicine and Immunotherapy Highlighted at ASCO 2018
Wayne Kuznar
August 2018 Vol 11, Special Issue
in
Conference Highlights ASCO
Cell-Free DNA Assays Could Result in a New Blood Test for Early Detection of Cancer
Wayne Kuznar
August 2018 Vol 11, Special Issue
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
August 2018 Vol 11, Special Issue
in
Immunotherapy
IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer
Wayne Kuznar
August 2018 Vol 11, Special Issue
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer
Wayne Kuznar
August 2018 Vol 11, Special Issue
in
Lung Cancer
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
Wayne Kuznar
August 2018 Vol 11, Special Issue
in
Multiple Myeloma
Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Lung Cancer
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Breast Cancer
CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Multiple Myeloma
ASCO President Lists Progress Made in Cancer, Highlighting Current Priorities
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Prostate Cancer
In Chronic Myeloid Leukemia, Selection of Tyrosine Kinase Inhibitors Depends on Variables Other Than Survival
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Leukemia
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Emerging Therapies
Dacomitinib Represents Potential New Targeted Therapy for EGFR Mutation–Positive Lung Cancer
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Emerging Therapies
Maintenance Treatment in Mantle-Cell Lymphoma Extends Survival
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights
in
Lymphoma
Lenalidomide Maintenance Therapy Extends Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Leukemia
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Multiple Myeloma
Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Lymphoma
Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Lymphoma
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Emerging Therapies
Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Multiple Myeloma
The Hematology Pipeline Features New Immune Therapies, and Targeted Agents
Wayne Kuznar
February 2017 Vol 10, Special Issue: Payers’ Perspectives In Oncology: ASH 2016 Highlights
in
Emerging Therapies
Cost, Access, and Delivery Challenge New Oncology Drug Options
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
Value-Based Oncology Management and Outcomes-Based Contracting
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
Cost-Savings Measures Will Dot the Oncology Landscape
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
ASCO CEO Addresses Quest for Value in Cancer Care
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
Quality Measures Are Key to Supporting Drug Value
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
Cancer Treatment Costs and Trends Beckon Risk-Sharing Future
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
PhRMA’s Perspective on Value-Driven Healthcare
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
AVBCC Sixth Annual Conference: The Evolution of Value-Based Cancer Care
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
in
Conference Correspondent
Practice Transformation Essential to the Oncology Care Model
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
Specialty Pharmacies Add Value in the Management of Cancer Drugs
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
Genomic Assays Expediting Adoption of Personalized Cancer Therapy in Clinical Practice
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
Maximizing the Potential of Immunotherapy the Focus of Cancer Moonshot 2020
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
in
Immunotherapy
Employers Look to Manage the Benefits of Specialty Pharmacy
Wayne Kuznar
December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights
in
Employers’ Perspective
CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
Nivolumab plus Ipilimumab Combination Promotes Durable Responses in Advanced Lung Cancer
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Lung Cancer
Alectinib Potential First-Line Treatment for NSCLC Associated with ALK Mutation
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Lung Cancer
Novel Vaccine Induces Immunologic Responses in Patients with Acute Myeloid Leukemia
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Novel Chimeric Monoclonal Antibody Improves Survival in Advanced Gastric Cancers
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Adding the BCL-2 Inhibitor Venetoclax to Treatment Regimen Promising in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
ASCO President Addresses Quality Care Through Collective Wisdom
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
The Oncology Drug Pipeline Shows No Evidence of Slowing Down
Wayne Kuznar
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Oncology Pipeline Full, and Not Just with Immunotherapies
Caroline Helwick
,
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Care Pathway for NSCLC Cuts Chemotherapy Cost
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Nivolumab Makes Headwinds into Liver Cancer
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
ASP plus 6% Will Fall by the Wayside, but What Are the Alternatives?
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Monthly Care Management Payments Called “Win-Win-Win” Reform
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Enhanced Reimbursement for Oncology Services Pays for Patient-Centered Care
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
The Push Toward Value-Based Payment for Oncology
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers
Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
CAR-T Achieves High Rate of Remission in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Pracinostat-Azacitidine Combination Generates Responses in Older Adults with Acute Myeloid Leukemia
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Leukemia
Immunotherapy with PD-1 Inhibitors the Newest Breakthrough in Hodgkin Lymphoma
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Lymphoma
Orphan Drug Expenditures in the United States Expected to Stabilize
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML
Wayne Kuznar
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
The Hematology Pipeline Is Abundant
Wayne Kuznar
,
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Breast Cancer
Necitumumab Extends Survival of Patients with Squamous Lung Cancer
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Lung Cancer
Federal Spending on Cancer Research and Access to Care Woefully Inadequate
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Upfront Docetaxel Markedly Improves Survival in Metastatic Prostate Cancer, at Reduced Cost
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Prostate Cancer
Should Oncologists Consider Interests of Society at Large When Treating the Individual Patient?
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Even When Adjusting for Improved Survival, Newer Cancer Drugs More Expensive Than Older Ones
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Patients with Cancer Are Not Asking for Costly, Excessive Treatments
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
2014 Oncology Pipeline Looks Impressive
Caroline Helwick
,
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Emerging Therapies
Payment Reform Key to Value-Based Cancer Care
Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Rituximab Maintenance and Radioimmunotherapy Are Cost-Effective After First-Line Therapy in Follicular Lymphoma
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Idelalisib Improves Outcomes in Heavily Pretreated Patients with CLL
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Leukemia
Hospital Readmission After Stem-Cell Transplant Decreases Survival
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Conference Highlights ASH
JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Conference Highlights ASH
Surveillance Scanning in Transformed Indolent Lymphoma of Limited Clinical Benefit
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Lymphoma
Promise of Genomic Sequencing for Clinical Decision-Making in Hematopoietic Cancers
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Nilotinib Sustains Deeper Molecular Response versus Imatinib in Patients with Ph+ CML
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Leukemia
Novel Anti-CD20 Antibodies Show Promising Results in Unfit Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Leukemia
Rituximab Infusions Costlier When Given in the Hospital
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Physicians Must Consider the Financial Burden of Allogeneic Transplants
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Promising Drugs in the Pipeline for Leukemia and Myelodysplastic Syndromes
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Leukemia
Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML
Wayne Kuznar
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
New Data Show Ranolazine Most Effective Antianginal Agent for Patients with Type 2 Diabetes and HbA1c >7%
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights
Financial Incentives Can Promote Maintenance of Weight Loss, a Major Factor in Diabetes
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights
Future of Healthcare Reform: Expect New Payment and Delivery Models
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights
GLP-1 Agonists May Protect Patients with Diabetes from Heart Failure
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights
in
Emerging Therapies
Look AHEAD: Lifestyle Intervention Cost-Effective in Overweight Patients with Type 2 Diabetes
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights
SGLT-2 Inhibitors Show Durability in Glycemic Control, Weight-Loss Maintenance
Wayne Kuznar
August 2013, Vol 6 ADA 2013 Highlights
in
Emerging Therapies
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
New Analysis Confirms Radium Ra-223 Prolongs Survival in Patients with Metastatic CRPC, Regardless of Previous Docetaxel Therapy Status
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
in
Prostate Cancer
Lack of Knowledge Prevents Men with Early-Stage Prostate Cancer from Choosing Active Surveillance
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
in
Prostate Cancer
New Data Confirm Benefits of 10 Years Tamoxifen versus 5 Years in Patients with ER-Positive Breast Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
in
Breast Cancer
Current Treatment of Advanced NSCLC Requires Testing for Driver Mutations
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
in
Lung Cancer
Afatinib Doubles Progression-Free Survival Compared with Chemotherapy in Patients with Lung Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
in
Lung Cancer
Dabrafenib Shows Promising Results in Patients with Stage IV NSCLC
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
in
Lung Cancer
Mammography Screening Rates Enhanced by Copay Elimination
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
Causes of Hospital Readmissions of Patients with Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
Poor Adherence to Oral Cancer Drugs a Growing Concern
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
Use of High-Cost Diagnostic Tests for Lung Cancer Surveillance Rising
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
Essential Health Benefits, Comparative Effectiveness Research, Payment Models All Play a Role in the ACA
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
Variations in Cancer Treatment Raise Average Cost of Care by $25,000 per Patient
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
ASCO President Highlights Bridges to Conquer Cancer
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
Cancer Drug Pipeline Is Bustling
Caroline Helwick
,
Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
Weight Loss Intervention Fails to Reduce Cardiovascular Events in Type 2 Diabetes, but Has Positive Effect on Other Measures
Wayne Kuznar
Web Exclusives
Low-Cost Phone Intervention Helps with Weight Loss, Glycemic Control
Wayne Kuznar
Web Exclusives
Symptomatic hypoglycemia increases risk of cardiovascular events, death in type 2 diabetes
Wayne Kuznar
Web Exclusives
Achieving glucose, blood pressure, and lipid targets improving among diabetic patients, but there’s still long way to go
Wayne Kuznar
Web Exclusives
Cardiovascular data confirm metformin over sulfonylurea as initial treatment choice in type 2 diabetes
Wayne Kuznar
Web Exclusives
in
Cardiometabolic Health
Does insulin increase the risk of type 2 diabetes-related complications?
Wayne Kuznar
Web Exclusives
PET-Directed Approach to Treating Early-Stage Hodgkin Lymphoma Produces Excellent Outcomes
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue
in
Lymphoma
NIH Research Funding Cuts Would Have Devastating Impact on Hematology
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue
Alternatives to “7 + 3” Induction Therapy for AML Are Emerging
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue
in
Leukemia
Fast Response Identifies Patients with CML for Entry into Studies of Imatinib Discontinuation
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue
in
Leukemia
New Oral TKI Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue
in
Leukemia
Combined Chemoradiation Cost-Effective in Younger Patients with Primary CNS Lymphoma
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue
Selective JAK Inhibitor Cost-Effective Option for Patients with Myelofibrosis
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue
New Targeted Agent Shows Significant Success in Treating Refractory Form of AML
Wayne Kuznar
February 2013 Vol 6, No 1, Special Issue
in
Leukemia
Measuring Coronary Calcium in Patients with Type 2 Diabetes Improves CVD Risk Assessment
Wayne Kuznar
Web Exclusives
CABG Surgery Outcomes Superior to PCI and Cost-Effective in Patients with Diabetes and Multivessel CAD
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
Probiotic Reduces LDL Cholesterol Level
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
Not All Omega-3 Fatty Acids Have the Same Effects on Lipids
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
Alternative Anticoagulants to Warfarin Reduce Vascular Risk in Patients with NVAF
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
in
Cardiometabolic Health
Lipid Therapy Update: HDL Therapies Falling Short, Promising LDL Agents, 2 Potential Treatments for Familial Hypercholesterolemia
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
New Hypertension Guidelines Will Be Strictly Evidence-Based
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
Behavioral Interventions Can Result in Weight Loss
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
Interventions for Cardiovascular Risk Reduction in Type 2 Diabetes Must Be Multifactorial
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
in
Cardiometabolic Health
Several Antihypertensive Drug Combinations Increase the Risk for Incident Diabetes
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
in
Cardiometabolic Health
Control of 4 Risk Factors Would Slash CHD Rate in Diabetes by Half
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
in
Cardiometabolic Health
GLP-1 Agonism Holds Promise for Preventing Macrovascular Disease in Type 2 Diabetes
Wayne Kuznar
Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
in
Emerging Therapies
Weight loss from lifestyle changes does not reduce adverse cardiovascular outcomes in patients with type 2 diabetes
Wayne Kuznar
Web Exclusives
New ADA-EASD Position Statement on Managing Hyperglycemia in Type 2 Diabetes favors Individualized Approach
Wayne Kuznar
Web Exclusives
Mounting Evidence that DPP-4 Inhibitors may Reduce Cardiovascular Risk
Wayne Kuznar
Web Exclusives
Incretin Therapies Lower Cardiovascular Risk Score
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
in
Cardiometabolic Health
The Diabetes Epidemic Is Like a Tsunami Hitting in Waves
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
Diabetes Rates Surging Among American Youth
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
in
Cardiometabolic Health
Primary Care Physicians Underdiagnose Chronic Kidney Disease in Diabetic Patients
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
Paying Patients to Change Their Health Behavior Is Effective
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
Value-Based Benefit Design: Reducing Copayment for High-Value Services Maximizes Return on Investment
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
DPP-4 Inhibitors Improve Glycemic Control in Elderly Patients with Diabetes
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
1 in 4 Patients with Type 2 Diabetes Does Not Take Basal Insulin as Prescribed
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
Quality Improvement Programs Enhance Diabetes Care, Especially When Baseline Measures Are Poor
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
Early Intensive Therapy in Type 2 Diabetes Preserves Beta-Cell Function
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
New Long-Acting Insulin Degludec Lowers Hypoglycemia Significantly versus Insulin Glargine
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
in
Emerging Therapies
The Ancient Anti-Inflammatory Drug Salsalate Lowers Blood Glucose Levels
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
in
Emerging Therapies
Diabetes Drug Pipeline: Promising Agents in Late Stages of Development
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
in
Emerging Therapies
Head-to-Head Comparison: Early Insulin Glargine Can Help Achieve Glycemic Target in Type 2 Diabetes
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
Glycemic Control in Patients with Type 2 Diabetes Significantly Lowers Cardiovascular Disease Risk
Wayne Kuznar
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
in
Cardiometabolic Health
Early Intensive Therapy in Type 2 Diabetes Preserves Beta-Cell Function
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
Quality Improvement Programs Enhance Diabetes Care, Especially When Baseline Measures Are Poor
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
1 in 4 Patients with Type 2 Diabetes Does Not Take Basal Insulin as Prescribed
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
Diabetes Drug Pipeline: Promising Agents in Late Stages of Development
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
in
Emerging Therapies
The Ancient Anti-Inflammatory Drug Salsalate Lowers Blood Glucose Levels
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
in
Emerging Therapies
Head-to-Head Comparison: Early Insulin Glargine Can Help Achieve Glycemic Target in Type 2 Diabetes
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
The Diabetes Epidemic Is Like a Tsunami Hitting in Waves
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
Novel Basal Insulin LY2605541 Lowers Blood Glucose, Enhances Weight Loss
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
in
Emerging Therapies
New Long-Acting Insulin Degludec Lowers Hypoglycemia Significantly versus Insulin Glargine
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
in
Emerging Therapies
Value-Based Benefit Design: Reducing Copayment for High-Value Services Maximizes Return on Investment
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
Diabetes Rates Surging Among American Youth
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
in
Cardiometabolic Health
Paying Patients to Change Their Health Behavior Is Effective
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
Primary Care Physicians Underdiagnose Chronic Kidney Disease in Diabetic Patients
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
Glycemic Control in Patients with Type 2 Diabetes Significantly Lowers Cardiovascular Disease Risk
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
in
Cardiometabolic Health
DPP-4 Inhibitors Improve Glycemic Control in Elderly Patients with Diabetes
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
Incretin Therapies Lower Cardiovascular Risk Score
Wayne Kuznar
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
in
Cardiometabolic Health
In Head-to-Head Comparison, Continuous Beats Intermittent Hormonal Therapy for Metastatic Prostate Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Prostate Cancer
A Promising New Gene Test to Differentiate Between Aggressive and Indolent Disease
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Prostate Cancer
Agent that Targets Heat Shock Protein Shows Activity in Castration-Resistant Prostate Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Prostate Cancer
Abiraterone Before Chemotherapy a Successful Strategy in Prostate Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Prostate Cancer
The Oncology Drug Pipeline Robust with Novel Agents
Caroline Helwick
,
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Pipeline
Family History of Cancer/Genetic Counseling Often Lacking for Patients First Presenting with Malignancy
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Cancer Therapies in Short Supply Prompt a Response at the Federal Level
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Axitinib Dose Titration Up Enhances Outcomes in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Renal-Cell Carcinoma
Non–Small-Cell Lung Cancer Testing Can Be Offered Routinely in Community Hospitals
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Lung Cancer
Quality of Life Drives Patient Preference for Metastatic RCC Drug
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Renal-Cell Carcinoma
Afatinib Boosts PFS in EGFR Mutation–Positive Lung Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Lung Cancer
Enzalutamide Extends Survival, Improves QOL in Advanced Prostate Cancer
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
in
Prostate Cancer
Levels of Gene Expression a New Noninvasive Way to Identify Obstructive CAD
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
in
Cardiometabolic Health
Triple-Antiplatelet Therapy Equal to Double-Dose Dual Therapy After Percutaneous Coronary Intervention
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
in
Cardiometabolic Health
Single-Agent Oral Regimen as Effective as Current Standard for Pulmonary Embolism, Less Bleeding
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
in
Cardiometabolic Health
Monoclonal Antibody Produces Powerful Reductions in LDL Cholesterol
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
Low-Potency Statins Initiated in High-Risk Patients in a Managed Care Setting
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
New Drug Therapies for Difficult-to-Control Atrial Fibrillation
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
Blood Assay for Galectin-3 Identifies Heart Failure Risk of Patients in the Community Setting
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
IMMEDIATE: Early Use of Inexpensive Glucose-Insulin- Potassium Solution Can Prevent Cardiac Arrest in ACS
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
Value of New Anticoagulants in Acute Coronary Syndrome Still Unclear
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
Consider Combination Therapy for Patients with Low- and High-Risk Hypertension
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
Lipid-Lowering Drug Pipeline: There Is Life After Statins
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
New Oral Anticoagulants Show Superior Efficacy versus Warfarin, and No Need for Monitoring
Wayne Kuznar
Value-Based Care in Cardiometabolic Health May 2012, Vol 1, No 1
Anti-VEGF Antibody Injections Improve Vision in Diabetic Macular Edema
Wayne Kuznar
Web Exclusives
in
Conference Highlights ADA
Artificial Pancreas Passes Test in Patients with Type 1 Diabetes
Wayne Kuznar
Web Exclusives
in
Conference Highlights ADA
Medical Food Improves Symptoms of Diabetic Neuropathy
Wayne Kuznar
Web Exclusives
in
Conference Highlights ADA
Education, Counseling Associated with Improved Clinical Outcomes in Type 2 Diabetes
Wayne Kuznar
Web Exclusives
in
Conference Highlights ADA
Treatment Satisfaction Highest for Diabetic Patients Taking Only Oral Medications
Wayne Kuznar
Web Exclusives
in
Conference Highlights ADA
Adding Saxagliptin to Metformin Improves Glycemic Control Over Uptitrating Metformin Dose
Wayne Kuznar
Web Exclusives
in
Conference Highlights ADA
Diabetes Prevention with Metformin Is Cost-Saving for Persons at High Risk
Wayne Kuznar
Web Exclusives
in
Conference Highlights ADA
Blood Glucose Testing a Significant Contributor to Pharmacy Costs in Patients Using Insulin
Wayne Kuznar
Web Exclusives
in
Conference Highlights ADA
Insulin Inappropriately Discontinued in Many Type 2 Diabetes Patients After Hospitalization
Wayne Kuznar
Web Exclusives
in
Conference Highlights ADA
Cutting-Edge Data Presented at ADA 2011 Highlight the Diabetes–Cardiovascular Disease Link
Wayne Kuznar
September/October 2011 Volume 4, Number 6
in
Conference Highlights ADA
Economic Recession Affects Rates of Cancer Incidence and Treatment
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue
Multiple Myeloma Treatments Are Moving Rapidly from Bench to Bedside
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue
in
Multiple Myeloma
Cabozantinib Shows Dramatic Effects on Bone Metastases in Advanced Prostate Cancer
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue
in
Prostate Cancer
Get Ready for the New Era of “Genomic Chaos” in Cancer Care
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue
Medicaid Reimbursement for Cancer Screening Lags Inflation
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue
Patients Want to Discuss Cost of Care, Oncologists Often Avoid It
Wayne Kuznar
August 2011 Vol 4, No 4, Special Issue
Novel Selective Beta-Agonist Improves Lung Function in COPD: Preliminary Analysis
Wayne Kuznar
Web Exclusives
First Acute COPD Exacerbation a Significant Risk for Death within 4 Years
Wayne Kuznar
Web Exclusives
Heading Off Exacerbations in COPD Is Crucial
Wayne Kuznar
Web Exclusives
Worsening Symptoms, Lung Function Precede COPD Exacerbations
Wayne Kuznar
Web Exclusives
Systemic Effects of COPD Linked to Many Comorbidities, Affect Treatment Decisions, Increase Costs
Wayne Kuznar
Web Exclusives
Roflumilast Improves Lung Function Independent of Inhaled Corticosteroids
Wayne Kuznar
Web Exclusives
Novel PDE 4 Inhibitor Cuts COPD Exacerbations
Wayne Kuznar
Web Exclusives
Dry Powder Inhalers Compared for Correct Use, Ease of Handling: Breezhaler versus HandiHaler
Wayne Kuznar
Web Exclusives
New Developments in Aerosol Delivery Aim to Improve Therapeutic Efficacy
Wayne Kuznar
Web Exclusives
Performance, Preference Vary for COPD Inhalers
Wayne Kuznar
Web Exclusives
Selecting an Inhalation Device for COPD Should Consider Peak Flow Rates, Patient Satisfaction
Wayne Kuznar
Web Exclusives
Expect Widespread Adoption of P4P as Healthcare Spending Increases
Wayne Kuznar
Web Exclusives
COPD Alliance Aims for Better Recognition and Care of COPD
Wayne Kuznar
Web Exclusives
COPD Treatment Complexity Affects Adherence, Resource Utilization
Wayne Kuznar
Web Exclusives
Burden of COPD on Older Employees Is Substantial
Wayne Kuznar
Web Exclusives
Total Annual COPD Costs Top $4000 per Patient
Wayne Kuznar
Web Exclusives
Emerging Drugs for COPD Target Lung Function, Inflammation, Smooth-Muscle Cells in Airways
Wayne Kuznar
Web Exclusives
Investigational Anticholinergic Achieves Early Bronchodilation
Wayne Kuznar
Web Exclusives
Patients with COPD and Their Caregivers Are Satisfied with Nebulizer Therapy
Wayne Kuznar
Web Exclusives
Chest 2010 Explores State-ofthe- Art Management of COPD and Treatments on the Horizon
Wayne Kuznar
Web Exclusives
Healthcare Reform Must Include Multiple Components
Wayne Kuznar
Web Exclusives
Bustling Pipeline for Diabetes and Its Metabolic Consequences
Wayne Kuznar
July/August 2008, Vol 1, No 6
Healthcare Reform Must Include Multiple Components
Wayne Kuznar
Web Exclusives
in
Health Policy and Reform
FDA WATCH
Wayne Kuznar
,
Nirav R. Shah, MD,MPH
,
F. Randy Vogenberg, PhD, FASHP
February/March 2009, Vol 2, No 2
in
FDA Approvals
,
Perspectives
Bustling Pipeline for Diabetes and Its Metabolic Consequences
Wayne Kuznar
July/August 2008, Vol 1, No 6
The Antiplatelet Drug Pipeline: Some Promising Candidates
Wayne Kuznar
November/December 2008, Vol 1, No 9
in
Conference Highlights AHA
An Overview of Cholesterol Management
Robyn A. Burns Schaiff, PharmD, BCPS
,
Wayne Kuznar
,
Richard M. Moe, MD, PhD
,
Daniel W. Krichbaum, PharmD
November/December 2008, Vol 1, No 9
in
Clinical
The Cardiovascular Pipeline: ACC 2010 Features Late-Stage Drugs
Wayne Kuznar
March/April 2010, Vol 3, No 2
in
Pipeline
Cardiology Pipeline Is Promising: AHA 2009
Wayne Kuznar
January/February 2010, Vol 3, No 1
in
Industry Trends
The Cardiology Pipeline
Wayne Kuznar
Web Exclusives
in
Pipeline
Diabetes Pipeline: New Strategies Emerging for Glycemic Control
Wayne Kuznar
Web Exclusives
in
Pipeline
Last modified: September 6, 2013
SUBSCRIBE
HOME
ABOUT
CONTACT US
TERMS OF USE
PRIVACY POLICY
ADVERTISING POLICY
© Amplity Health. All rights reserved.
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
AHDB
Special Print Editions
AHDB
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
AHDB
's
Privacy Policy
, and
AHDB
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION
